Skip to main content

Dr. Ryan E. Hall, M.D.

Hematology & Oncology (Hematology & Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
16
In the NPI registry since
2010
Medicare patients seen, 2024
1,431

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2010Medical school: University of Arkansas College of Medicine
  • 2010Registered with an NPI (national billing number; not a license date)

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    AR license E-9634
  • Medical Oncology Physician
    AR license E-9634

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
1,431
Services billed
379,557
Patients’ average age
74
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, nivolumab, 1 mg37,02025
Injection, pembrolizumab, 1 mg33,20050
Injection, oxaliplatin, 0.5 mg21,50031
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)19,38021
Injection, fosaprepitant, 1 mg16,80051
Injection, denosumab, 1 mg13,68066
Injection, aprepitant, 1 mg11,83034
Injection, paclitaxel protein-bound particles, 1 mg11,20015
Injection, dexamethasone sodium phosphate, 1 mg10,560229
Injection, azacitidine, 1 mg8,50013

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 4 companies reported 5 payments worth $88.44 in total to this clinician.

By company
Caris Mpi, Inc.$29.22
Genzyme Corporation$20.86
Gilead Sciences, Inc.$19.22
Azurity Pharmaceuticals, Inc.$19.14
By type
Food and Beverage$88.44

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Arkansas →

Industry-funded research

Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $741,879 in research payments for these studies, mostly to the institutions running them.

  • A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
    Beone Medicines Ltd. · Active, not recruiting · NCT04170283
  • A Phase 3 Study of Pembrolizumab in combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel followed by Pembrolizumab with or without maintenance MK 2870 in the First-line Treatment of Metastatic Squamous Non…
    Merck Sharp & Dohme LLC
  • Caris Biorepository Research Protocol
    Caris Mpi, Inc. · Recruiting · NCT01499394
  • A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy f…
    AstraZeneca Pharmaceuticals LP
  • A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Inelig…
    Merck Sharp & Dohme LLC
  • A phase 2 randomized doubleblind placebocontrolled study to investigate the efficacy safety and tolerability of ponsegromab in patients with cancer cachexia and elevated concentrations of GDF15 followed by an optional…
    Pfizer Inc.
  • A phase 2B3 randomized doubleblind study to investigate the efficacy safety and tolerability of ponsegromab PF06946860 compared with placebo both with background firstline chemotherapy in adult participants with cache…
    Pfizer Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Little Rock

Sources

NPI registry (CMS NPPES, November 2026; record last updated March 10, 2022), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1366761975. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.